Unknown

Dataset Information

0

Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: two randomised, double-blind, placebo-controlled, phase 1 and 2 trials.


ABSTRACT:

SUBMITTER: Yang S 

PROVIDER: S-EPMC7990482 | biostudies-literature | 2021 Aug

REPOSITORIES: biostudies-literature

altmetric image

Publications

Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: two randomised, double-blind, placebo-controlled, phase 1 and 2 trials.

Yang Shilong S   Li Yan Y   Dai Lianpan L   Wang Jianfeng J   He Peng P   Li Changgui C   Fang Xin X   Wang Chenfei C   Zhao Xiang X   Huang Enqi E   Wu Changwei C   Zhong Zaixin Z   Wang Fengze F   Duan Xiaomin X   Tian Siyu S   Wu Lili L   Liu Yan Y   Luo Yi Y   Chen Zhihai Z   Li Fangjun F   Li Junhua J   Yu Xian X   Ren Hong H   Liu Lihong L   Meng Shufang S   Yan Jinghua J   Hu Zhongyu Z   Gao Lidong L   Gao George F GF  

The Lancet. Infectious diseases 20210324 8


<h4>Background</h4>Although several COVID-19 vaccines have been developed so far, they will not be sufficient to meet the global demand. Development of a wider range of vaccines, with different mechanisms of action, could help control the spread of SARS-CoV-2 globally. We developed a protein subunit vaccine against COVID-19 using a dimeric form of the receptor-binding domain (RBD) of the SARS-CoV-2 spike protein as the antigen. We aimed to assess the safety and immunogenicity of this vaccine, ZF  ...[more]

Similar Datasets

| S-EPMC9009945 | biostudies-literature
| S-EPMC8366625 | biostudies-literature
| S-EPMC8823954 | biostudies-literature
| S-EPMC7712213 | biostudies-literature
| S-EPMC8994669 | biostudies-literature
| S-EPMC8366678 | biostudies-literature
| S-EPMC9679005 | biostudies-literature
| S-EPMC10206582 | biostudies-literature
| S-EPMC8541238 | biostudies-literature
| S-EPMC9187065 | biostudies-literature